Видео с ютуба Eunice Wang Md

AML on the Frontlines: Turning Trial Data Into Real-World Care

KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML

A Phase II trial investigating crenolanib plus salvage chemotherapy in R/R FLT3-mutated AML

The value and utility of MRD in the management of adults with newly-diagnosed AML

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO...

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO...

Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies

Expert Insights on Key Data From ASH 2020 on Acute and Chronic Leukemias

A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?

Congress to Clinic: Expert Takeaways on Emerging Data for AML

Hope for Relapsed AML: Ziftomenib Shows Promise in NPM1-Mutated Leukemia | Eunice Wang, MD | #EHA25

Dr. Eunice Wang discusses Secondary MDS

Real-world effectiveness and safety of CPX-351 in patients with secondary AML

Update on the KOMET-001 trial: ziftomenib in NPM1-mutant AML

The use of olutasidenib in R/R AML: an analysis of outcomes by number of prior treatment regimens

Advancing AML treatment: evidence-based regimens and guidelines for R/R AML management

Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

Episode 7 - Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System ...

Episode 8 - Conversations in Acute Myeloid Leukemia: Novel Therapies Targeting the Immune System ...

Top AML highlights from ASH 2024: what community oncologists should know